

# CNI RESEARCH LIMITED

A/120 GOKUL ARCADE SAHAR ROAD VILE PARLE EAST MUMBAI 400057

PHONE NO. 022-49737861 EMAIL – [chamatcar@chamatcar.com](mailto:chamatcar@chamatcar.com)

CIN NO. L45202MH1982PLC041643

**06-08-2024**

The Manager,  
Department of Corporate Services  
BSE Ltd.  
Dalal Street, Fort Mumbai – 400 001

**Sub: Outcome of Board Meeting held on 6<sup>TH</sup> August, 2024 at 11.30 AM.  
Ref.: Scrip Code: 512018**

---

Dear Sir/Madam,

This is to inform you that, pursuant Regulation 33 of the Listing Regulations, the meeting of Board of Directors of **CNI RESEARCH LIMITED** held on 06/08/2024 at 11.30 AM at the Registered Office of the Company transacted the following businesses:

1. Considered and Approve Un-audited Financial Results for quarter ended 30/06/2024 along with Limited Review Report.
2. Pleased to share the approved Business Strategy update for FY 2024-2025 with the stake holders.
3. Board has approved to change the name of the Company to "TOMORROW TECHNOLOGIES LIMITED" in view of its new business subject to all statutory approvals.

Kindly take the same on your records.

Meeting Start time: 11.30 AM

Meeting End time: **3: 30 PM**

Thanking you,

Yours Faithfully,

**FOR CNI RESEARCH LIMITED**

KISHOR  
PUNAMCHAND  
OSTWAL



**KISHOR OSTWAL**  
**MANAGING DIRECTOR**  
**DIN: 00460257**



CIN No.: L45202MH1982PLC041643

CNI RESEARCH LIMITED

CIN: L45202MH1982PLC041643

Registered Office: A-120, Gokul Arcade, Sahar Road Opp Garware House Vile Parle E, Mumbai, Maharashtra, 400057

## Statement of Standalone Unaudited Results for the Quarter ended 30/06/2024

|  |                              | (Rs. In Lacs/amount)                      |   |                          |            |
|--|------------------------------|---|---|--------------------------|------------|
|  |                              | Quarter Ended                             |   |                          | Year ended |
| Particulars  | 3 months ended<br>30/06/2024 | Preceding 3<br>months ended<br>31/03/2024 | Corresponding 3<br>months ended in<br>the previous<br>year 30/06/2023 | Year ended<br>31/03/2024 |            |
|  | (Unaudited)                  | (Audited)                                 | (Unaudited)   | (Audited)                |            |
| I Revenue From Operations  | 400.44                       | 278.01                                    | 242.75  | 962.44                   |            |
| II Other Income  | 18.12                        | 32.33                                     | 66.31   | 79.61                    |            |
| III <b>Total Income (I+II)</b>   | 418.55                       | 310.34                                    | 309.06  | 1042.05                  |            |
| IV <b>Expenses</b>   |                              |   |   |                          |            |
| Purchases of Stock-in-Trade  | 385.03                       | 266.08                                    | 232.49  | 908.22                   |            |
| Changes in inventories of finished goods,<br>Stock-in-Trade and work-in progress   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| Employee benefits expense  | 5.01                         | 3.33                                      | 7.06  | 18.08                    |            |
| Finance Costs  | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| Depreciation and amortisation expenses   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| Other Expenses   | 6.73                         | 12.82                                     | 7.85  | 30.76                    |            |
| <b>Total Expenses (IV)</b>   | 396.77                       | 282.23                                    | 247.40  | 957.06                   |            |
| V Profit/(loss) before exceptional items and<br>tax (I-IV)   | 21.78                        | 28.11                                     | 61.66   | 84.99                    |            |
| VI Exceptional Items   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| VII Profit/ (loss) before exceptions items and<br>tax(V-VI)  | 21.78                        | 28.11                                     | 61.66   | 84.99                    |            |
| VIII <b>Tax Expense:</b>   |                              |   |   |                          |            |
| (1) Current Tax  | 0.00                         | 1.44                                      | 0.00  | 1.44                     |            |
| (2) Deferred Tax   | 0.00                         | 0.04                                      | 0.00  | 0.04                     |            |
| IX Profit/(Loss) for the period from continuing<br>operations (VII-VIII)   | 21.78                        | 26.63                                     | 61.66   | 83.51                    |            |
| X Profit/(Loss) from discontinued operations   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| XI Tax expenses of discontinued operations   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| XII Profit/(Loss) from discontinued operations<br>(after tax) (X-XI)   | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| XIII Profit/(Loss) for the period (IX+XII)   | 21.78                        | 26.63                                     | 61.66   | 83.51                    |            |
| XIV <b>Other Comprehensive Income</b>  |                              |   |   |                          |            |
| (i) Fair valuation of Equity Instrument through<br>Other Comprehensive Income  | 148.81                       | -41.89                                    | 230.41  | 461.70                   |            |
| B. (i) Items that will be reclassified to profit or<br>loss  | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| XV <b>Total Comprehensive Income for the period<br/>(XIII+XIV) Comprising Profit (Loss) and Other<br/>Comprehensive Income for the period)</b> | 170.59                       | -15.26                                    | 292.07  | 545.21                   |            |
| XVI <b>Earnings per equity (for Continuing<br/>operation):</b>   |                              |   |   |                          |            |
| (1) Basic  | 0.02                         | 0.02                                      | 0.05  | 0.07                     |            |
| (2) Diluted  | 0.02                         | 0.02                                      | 0.05  | 0.07                     |            |
| XVII <b>Earnings per equity (for discontinued<br/>operation)</b>   |                              |   |   |                          |            |
| (1) Basic  | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| (2) Diluted  | 0.00                         | 0.00                                      | 0.00  | 0.00                     |            |
| XVIII <b>Earning per equity share (for discontinued &amp;<br/>continuing operation)</b>  |                              |   |   |                          |            |
| (1) Basic  | 0.02                         | 0.02                                      | 0.05  | 0.07                     |            |
| (2) Diluted  | 0.02                         | 0.02                                      | 0.05  | 0.07                     |            |

## Notes:

- The above results were reviewed by the Audit Committee and thereafter taken on record by the Board in its meeting held on 06/08/2024 and also the Limited review was carried out by the Statutory Auditors.
- Previous year figure have been regrouped wherever necessary.
- Financial Results for all the periods presented have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time

FOR CNI RESEARCH LIMITED

Date :- 06/08/2024

Place :- MUMBAI

KISHOR OSTWAL

Director

DIN: 00460257

**Cni Research Limited**

## ANNEXURE IV

Format for Reporting of Segment wise Revenue, Results and Capital Employed along with quarterly results

(Rs. In Lakhs)

| Particulars  | QUARTER ENDED                |  |   | YEAR ENDED               |
|--|------------------------------|--|---|--------------------------|
|  | 3 months ended<br>30/06/2024 | Preceding 3 months ended<br>31/03/2024 | Corresponding 3 months ended in the previous year<br>30/06/2023 | Year ended<br>31/03/2024 |
|  | (Unaudited)                  | (Audited)                              | (Unaudited)   | (Audited)                |
| 1. Segment Revenue (net sale / income from each segment should be disclosed under this head) |                              |  |   |                          |
| (a) Segment - Content Sale   | 6.08                         | 7.96                                   | 4.76  | 26.76                    |
| (b) Segment - Research Product Sale  | 0.00                         | 0                                      | 0.02  | 0.02                     |
| (c) Segment - Equity   | 394.36                       | 293.09                                 | 237.97  | 1002.41                  |
| (d) Segment - Other Business Income  | 18.12                        | 9.29                                   | 66.31   | 12.86                    |
| (e) Unallocated  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| <b>Total</b>   | <b>418.55</b>                | <b>310.34</b>                          | <b>309.06</b>   | <b>1042.05</b>           |
| Less: Inter Segment Revenue  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| <b>Net Sales/Income from operations</b>  | <b>418.55</b>                | <b>310.34</b>                          | <b>309.06</b>   | <b>1042.05</b>           |
| 2. Segment Results (Profit) (+)/ (Loss (-) before tax and interest from Each segment)#       |                              |  |   |                          |
| (a) Segment - Content Sale   | (5.67)                       | 2.76                                   | (10.16)   | (11.12)                  |
| (b) Segment - Research Product Sale  | 0.00                         | 0                                      | 0.02  | 0.02                     |
| (c) Segment - Equity   | 9.33                         | 16.06                                  | 5.48  | 83.23                    |
| (d) Segment - Other Business Income  | 18.12                        | 9.29                                   | 66.31   | 12.86                    |
| (e) Unallocated  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| <b>Total</b>   | <b>21.78</b>                 | <b>28.11</b>                           | <b>61.66</b>  | <b>84.99</b>             |
| Less: (i) Interest**   | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| (ii) Other Un-allocable Expenditure net off  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| (iii) Un-allocable income  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| <b>Total Profit Before Tax</b>   | <b>21.78</b>                 | <b>28.11</b>                           | <b>61.66</b>  | <b>84.99</b>             |
| 3. Capital Employed  |                              |  |   |                          |
| (Segment assets - Segment Liabilities)   |                              |  |   |                          |
| (a) Segment - Content Sale   | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| (b) Segment - Research Product Sale  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| (c) Segment - Equity   | 1397.61                      | 1243.74                                | 1047.19   | 1243.74                  |
| (d) Segment - Other Business Income  | 0.00                         | 0.00                                   | 0.00  | 0.00                     |
| (e) Unallocated  | 268.41                       | 249.96                                 | 194.54  | 249.96                   |
| <b>Total</b>   | <b>1666.02</b>               | <b>1493.71</b>                         | <b>1241.73</b>  | <b>1493.71</b>           |

# Profit / loss before tax and after interest in case of segments having operations which are primarily of financial nature.

\*\* Other than the interest pertaining the segments having operations which are primarily of financial nature.


For CNI RESEARCH LTD.

Date : - 06/08/2024

Place : - Mumbai

MR. KISHOR OSTWAL  
MANAGING DIRECTOR





# CNI GLOBAL BIZ

Know what you own, and know why you own it




## TOMORROW TECHNOLOGIES

### COMPANY GUIDANCE FY25



# Business Strategy Update



- Consortium will transfer perpetual South Asia IP & Technology Rights to EVEREST
- Company will be the global DevOps KPO for Consortium + offer services to other emerging tech cos as a global Emerging Tech DevOps Center of Excellence
  - Leverage acquired skills & capabilities to develop own emerging tech IPs

# Business Pivot to Emerging Tech

- Company shall enter the business of developing emerging tech IP as well as monetizing the IP through applications, software sales, platform services and other related activities.
- Either organically, or via acquisition, set up a tech development & operations (DevOps) KPO for emerging technologies.
- **Value Creation:**
  - Global DevOps KPO for the consortium, directly or via additional subsidiaries (domestic or foreign) for all IPs of the consortium companies, for which it shall receive compensation at an appropriately determined value.
    - This business has potential to further scale up by becoming the world's only dedicated DevOps KPO focused on emerging technologies.
  - Manage India domestic billing for applications, software sales, platform services and other related activities of the consortium companies natively and repatriate (subject to transfer pricing rules).
  - Based on its growth & potential, the Company via the DevOps KPO would also develop & manage its own emerging tech IPs focused globally to which the consortium would dedicate significant time and energy.
  - Company shall own all the IP developed by it making it a key player in the emerging technologies domain

# Planned Business SBUs

Multi-sensor multi-axis sports tech providing AI analytics & biomechanical visualization for aspiring pro athletes


World's first and only AI-powered unicommerce bot platform providing real time predictive analytics

Planned M&A of early stage emerging tech businesses with high-growth potential.

World's first and only corporate asset tokenization platform - provides a turnkey service helps brands leverage high-value real world assets

Super-fast, secure, hardware-based POS-less platform to support instant cashless micro-payments with 100% privacy.

# Revenue Mix





## Disclaimer

This presentation contains forward-looking statements, inter-alia, to enable investors to comprehend company's prospects and take informed investment decisions. This report and other statements - written and oral - that we periodically make, contain forward-looking statements that set out anticipated results based on the management's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipate', 'estimate', 'expects', 'projects', 'intends', 'plans', 'believes' and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward-looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is, inter-alia, subject to assumptions, risks, uncertainties, including but not limited to our ability to successfully conclude and integrate (potential) acquisition(s) and general regulatory and economic conditions affecting the industry. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated, expected or projected. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Further this presentation may also contain references to findings of various reports available in public domain. We make no representation as to their accuracy or that we necessarily subscribe to those findings. Figures for previous periods / year have been regrouped, wherever necessary.

# Thank You

[info@cniresearchltd.com](mailto:info@cniresearchltd.com)

[info@tomorrowtechnologies.in](mailto:info@tomorrowtechnologies.in)

---